Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Fox

Showing results (101-110 of 182) with videos related to

Pageof 19
Sort By:
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Antiviral Therapy|October 14, 2015
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, et al.
Plos One|May 8, 2026
Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018-2022 HIV vaccine preparedness cohort in Masaka, UgandaSylvia Kusemererwa, Sheila Kansiime, Gertrude Mutonyi, et al.
Journal of Virology|October 29, 2005
Sexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variantsAnita Milicic, Charles T T Edwards, Stéphane Hué, et al.
Trials|November 11, 2025
Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)Sylvia Kusemererwa, Bernadette Nayiga, Limakatso Lebina, et al.
HIV Medicine|August 29, 2024
Cardiovascular disease risk in people of African ancestry with HIV in the United KingdomStephanie Ko, Lourdes Dominguez-Dominguez, Zoe Ottaway, et al.
JAMA|March 11, 2010
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trialMark Loeb, Margaret L Russell, Lorraine Moss, et al.
AIDS Care|April 14, 2020
The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIVDanielle Solomon, Caroline A Sabin, Fiona Burns, et al.
African Journal of AIDS Research : AJAR|April 1, 2022
The potential effect of pre-exposure prophylaxis (PrEP) roll-out on sexual-risk behaviour among adolescents and young people in East and southern AfricaAndrew Sentoogo Ssemata, Richard Muhumuza, Lynda Stranix-Chibanda, et al.
Pageof 19

Showing results (101-110 of 182) with videos related to

Sort By:
Pageof 19
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Antiviral Therapy|October 14, 2015
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, et al.
Plos One|May 8, 2026
Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018-2022 HIV vaccine preparedness cohort in Masaka, UgandaSylvia Kusemererwa, Sheila Kansiime, Gertrude Mutonyi, et al.
Journal of Virology|October 29, 2005
Sexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variantsAnita Milicic, Charles T T Edwards, Stéphane Hué, et al.
Trials|November 11, 2025
Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)Sylvia Kusemererwa, Bernadette Nayiga, Limakatso Lebina, et al.
HIV Medicine|August 29, 2024
Cardiovascular disease risk in people of African ancestry with HIV in the United KingdomStephanie Ko, Lourdes Dominguez-Dominguez, Zoe Ottaway, et al.
JAMA|March 11, 2010
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trialMark Loeb, Margaret L Russell, Lorraine Moss, et al.
AIDS Care|April 14, 2020
The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIVDanielle Solomon, Caroline A Sabin, Fiona Burns, et al.
African Journal of AIDS Research : AJAR|April 1, 2022
The potential effect of pre-exposure prophylaxis (PrEP) roll-out on sexual-risk behaviour among adolescents and young people in East and southern AfricaAndrew Sentoogo Ssemata, Richard Muhumuza, Lynda Stranix-Chibanda, et al.
Pageof 19